The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The incidence and predictive factors of hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI).
 
Yeun Ho Lee
No Relationships to Disclose
 
Hyeonseon Kim
No Relationships to Disclose
 
Il-Young Chung
No Relationships to Disclose
 
Chiwoo Song
No Relationships to Disclose
 
Leeseul Kim
No Relationships to Disclose
 
Horyun Choi
No Relationships to Disclose
 
Jinah Kim
No Relationships to Disclose
 
Youjin Oh
No Relationships to Disclose
 
Grace Yujin Lee
No Relationships to Disclose
 
Heayoon Cho
No Relationships to Disclose
 
Young Kwang Chae
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Counsyl; Foundation Medicine; Guardant Health; Hanmi; Immuneoncia; Lilly; Lunit; Roche/Genentech; Takeda; Tempus
Speakers' Bureau - AstraZeneca; G1 Therapeutics; Genentech/Roche; Jazz Pharmaceuticals; Lilly; Merck
Research Funding - Abbvie; Biodesix; Bristol-Myers Squibb; Freenome; Lexent Bio
Travel, Accommodations, Expenses - Hanmi